Physician profile
David C Rioux
NPI 1316084650
$10,416.89
in general payments reported to CMS, 2019-2025
32 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $1,358 · 2021: $1,750 · 2022: $1,638 · 2023: $1,273 · 2024: $1,581 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,190.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,152.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $995.90 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $904.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $899.60 | 2019-2025 | Ozempic, Rybelsus |
| Lundbeck LLC | $736.54 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $692.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $646.25 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Abbvie INC. | $602.79 | 2020-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $458.93 | 2021-2025 | |
| Astellas Pharma US INC | $426.50 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $398.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $397.29 | 2019-2024 | Xarelto |
| Allergan, INC. | $280.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.73 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $256.90 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $186.65 | 2022-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $175.74 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $162.78 | 2019-2023 | Jardiance, Emgality |
| E.R. Squibb & Sons, L.L.C. | $154.84 | 2019-2024 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.64 | 2022-2025 | Caplyta |
| Eisai INC. | $112.49 | 2020-2021 | |
| Corcept Therapeutics | $84.17 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $72.12 | 2022 | |
| Paratek Pharmaceuticals, INC. | $32.44 | 2025 | Nuzyra |
| Aimmune Therapeutics, INC. | $30.07 | 2025 | Zenpep |
| Axsome Therapeutics, INC. | $27.53 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $27.08 | 2019 | |
| Inspire Medical Systems, INC. | $25.11 | 2023 | Inspire |
| Sumitomo Pharma America, INC. | $22.36 | 2025 | Gemtesa |
| Radius Health, INC. | $16.95 | 2020 | |
| Amgen INC. | $15.96 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.91 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rioux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.